Vanda Pharmaceuticals (NASDAQ:VNDA) Issues Quarterly Earnings Results

Vanda Pharmaceuticals (NASDAQ:VNDA) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.46), FiscalAI reports. Vanda Pharmaceuticals had a negative return on equity of 45.02% and a negative net margin of 127.41%.The business had revenue of $50.53 million for the quarter, compared to analyst estimates of $61.92 million.

Here are the key takeaways from Vanda Pharmaceuticals’ conference call:

• Fanapt continued strong growth: Second-quarter prescriptions rose 31% year over year and net product sales increased 23% to $36.0 million, supported by the bipolar I disorder launch and an expanded sales force.
• Multiple pipeline and commercial catalysts are approaching: BYSANTI is expected to launch in the second half of 2026, Quimilza has a December 2026 FDA action date, and late-stage readouts for NEREUS, VQW-765, and HETLIOZ are expected by year-end.
• Profitability and cash usage deteriorated: Second-quarter net loss widened to $62.5 million from $27.2 million a year earlier, while operating expenses rose 25% to $114.3 million; management expects 2026 cash burn to exceed 2025 levels.
• HETLIOZ sales remain pressured by generic competition: Second-quarter revenue fell 66% to $5.6 million, although approximately $7 million of shipments delayed until July will be recognized in the third quarter.
• NEREUS launch results remain difficult to assess: The product generated $1.0 million in recognized sales, while $12.6 million of wholesaler-related revenue was constrained because of uncertainty around patient demand and potential returns from elevated inventory levels.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA opened at $5.11 on Friday. The company’s fifty day moving average is $5.81 and its 200-day moving average is $6.76. Vanda Pharmaceuticals has a 12 month low of $4.14 and a 12 month high of $9.94. The firm has a market cap of $307.29 million, a price-to-earnings ratio of -1.10 and a beta of 0.64. The company has a quick ratio of 2.15, a current ratio of 2.16 and a debt-to-equity ratio of 0.01.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. boosted its stake in Vanda Pharmaceuticals by 456.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 5,328 shares during the period. Quarry LP bought a new stake in shares of Vanda Pharmaceuticals in the third quarter valued at approximately $53,000. Cerity Partners LLC acquired a new stake in shares of Vanda Pharmaceuticals in the second quarter worth $69,000. Boothbay Fund Management LLC bought a new position in Vanda Pharmaceuticals during the third quarter worth $72,000. Finally, Engineers Gate Manager LP acquired a new position in Vanda Pharmaceuticals during the 2nd quarter valued at $75,000. 88.14% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have weighed in on VNDA. HC Wainwright reissued a “buy” rating on shares of Vanda Pharmaceuticals in a report on Thursday, June 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Friday, July 17th. Finally, Wall Street Zen downgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $14.30.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.